Lapatinib Base CAS 231277-92-2 Puritas ≥99.0% (HPLC)
Nomen chemicum | Lapatinib Base |
Synonyma | Lapatinib;N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
CAS Number | 231277-92-2 |
Stock Status | In Stock |
Formulae hypotheticae | C29H26ClFN4O4S |
M. Pondus | 581.06 |
Liquescens punctum | 141.0~149.0℃ |
Density | 1.381±0.06 g/cm3 |
COA & MSDS | Praesto |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Fere Alba aut lux Yellow Crystallina pulveris |
Lepidium sativum | IR;HPLC |
Puritas / Analysis Methodus | ≥99.0% (HPLC) |
Liquescens punctum | 141.0~149.0℃ |
Damnum in Siccatio | ≤0.50% |
Residere in Ignition | ≤0.10% |
Metalla gravia (ut Pb) | ≤20ppm |
Organicum volatile immunditias | Occurrit opus est |
Substantiae cognatae | |
una immunditia | ≤0.30% |
Totalis immunditias | ≤1.00% |
Test Standard | Enterprise Standard |
Fasciae vita | II annis cum rite condita |
Consuetudinem | API, Curatio oris pro Cancro |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
![1](https://a395.goodao.net/uploads/15.jpg)
![www.ruifuchem.com](https://a395.goodao.net/uploads/Factory-Shanghai-Ruifu-Chemical-Co.-Ltd.-www.ruifuchemical.com_3.png)
API (CAS: 231277-92-2)est therapia iaculis therapia of cancer pectus medicamentum, est inhibitor kinasus tyrosinus, potest efficaciter inhibere factorem receptoris humani epidermalis incrementi -1 (ErbB1) et factor incrementi epidermalis humani receptoris (ErbB2) activitatem kinasi tyrosini -2.Unicum est quod variis modis munus agere potest, ut cancer cellulae pectoris signum ad incrementum necessarium recipere non possit.Mechanismus actionis est inhibere intracellulares EGFR (ErbB-1) et HER2 (ErbB-2) ATP sites, ne phosphorylationem et activationem cellularum tumoris impediret et descensum ordinationem significandi ab EGFR (ErbB-1) et HER2 (ErbB-1) duo aggregata homogenea et heterogenea.Compositio (CAS: 231277-92-2) cum Capecitabine tractat aegros cum carcinomate provectio vel metastatico pectoris cum overexpressione receptoris humani epidermalis, cum anthracyclinis, paclitaxel et trastuzumab iam tractatis.De iudiciis clinicis demonstraverunt etiam efficaciter tractari HER2-type de aegris cancer cum resistentia Herceptin.
Lapatinib in compositione cum Capecitabine apta est curationi carcinomatis progressi vel metastatici aegroti cum HER2(ErbB-2 overexpression) et praecedente curatione inter anthracyclinos, paclitaxel et trastuzumab.
In vitro Lapatinib tabulae CYP3A4 et CYP2C8 in therapeuticis con- ceptionibus inhibere possunt, et maxime metabobilia sunt CYP3A4.medicinae quae hanc enzyme actionem inhibent signanter augere possunt sanguinem pharmacum pharmacum concentrationis Lapatinib.Ketoconazole, 0.2g singulis diebus, 2 vicibus/d, augere potest auc Lapatinib per 3~7 tempora et vitam dimidiam per 1.7 vicibus post 7 dies prorogare.Voluntarii sani ore CYP3A4 inducentes viva voce, 100 mg utrobique, bis in die, mutati sunt ad 200mg singulis vicibus post 3 dies, communicantes 17 dies bis in die.A. C. de Lapatinib% minui LXXII.Lapatinib terra oneraria est ad P-glycoprotein, et medicamenta quae glycoprotein inhibent sanguinem medicamentorum concentratione augere possunt.
Novum medicamentum Lapatinib est iaculis justo pretium turpis a GlaxoSmithKline, UK.Inhibitor tyrosinus est qui efficaciter inhibere potest factorem receptoris humani epidermalis incrementi -1(ErbB1) et factor humanus epidermalis incrementi receptoris -2(ErbB2) kinasi activitatem tyrosinam.Unicum est quod variis modis fungi potest ut cancer cellulae pectoris signa ad incrementum necessaria recipere non possit.Mechanismus actionis est inhibere sites ATP EGFR(ErbB-1) et HER2(ErbB-2) in cellulis ne phosphorylationem et activationem cellularum tumoris et signa per deflexiones homogeneas et heterogeneas dimersas EGFR(ErbB obstruant. -1) and HER2(ErbB-1).Theraphim hypotheticum iaculis pro cancro mammae ad tractationem oncogenis pertinentia et expressio producta cognata ad eventum et progressionem cancri pectoris.Medicamenta hypothetica iaculis inhibent vel occidunt cellulas tumores obcludunt translationi signo in cellulis tumore vel cellulis affinibus ad mutationes in locutionibus e gene cellularum coercendis.die XIV mensis Martii, MMVII, US cibum et pharmacum administratio approbavit iuncturam lapatinib et xeloda (capecitabinae) ad curationem aegroti carcinomatis metastatici progressi vel cordis humani receptoris 2(ErbB2) receptoris epidermalis expressae et tractatae cum anthracyclinis, paclitaxel et trastuzumab .Orci probationes ostendunt hoc productum etiam effectus bonos clinicos habere pro aegris cancer pectoris HER2 qui medicamento resistentiam evolvit ad Herceptin Roche (Herceptin).lapatinib est novum medicamento iaculis anticancer.Potest agere in Her-1 et Her-2 scuta simul.Effectus biologicus huius modi agendi in prolificatione et incremento cellularum tuberculorum multo maior est quam unus tantum scopus.Sic dicta medicamenta therapeutica iaculis medicamenta spectant ad medicamenta quae aliquos receptores, gena vel clavos servo utentes ut scuta ad necem pertinentium cellas tumoris modo iaculis.
-
Lapatinib Base CAS 231277-92-2 Puritas ≥99.0% (H...
-
Lapatinib Ditosylate Monohydrate CAS 388082-78-...
-
Sodium Methanesulfinate CAS 20277-69-4 Munditia >...
-
2-Aminoethyl Methyl Sulfone Hydrochloride CAS 1...
-
Lapatinib Intermediate CAS 231278-84-5 Puritas >...
-
6-Iodo-4-Hydroxyquinazoline CAS 16064-08-7 Puri...
-
3-Chloro-4-(3-Fluorobenzyloxy)aniline CAS 20219...
-
4-Chloro-6-Iodoquinazoline CAS 98556-31-1 Purit...
-
5-Formyl-2-Furanboronic Acidum CAS 27329-70-0 Pur...